收费全文 | 374004篇 |
免费 | 20938篇 |
国内免费 | 1084篇 |
耳鼻咽喉 | 4557篇 |
儿科学 | 11663篇 |
妇产科学 | 7324篇 |
基础医学 | 52066篇 |
口腔科学 | 8192篇 |
临床医学 | 32099篇 |
内科学 | 80905篇 |
皮肤病学 | 8205篇 |
神经病学 | 34143篇 |
特种医学 | 11628篇 |
外国民族医学 | 106篇 |
外科学 | 49047篇 |
综合类 | 3057篇 |
现状与发展 | 1篇 |
一般理论 | 230篇 |
预防医学 | 33648篇 |
眼科学 | 8244篇 |
药学 | 26224篇 |
5篇 | |
中国医学 | 1127篇 |
肿瘤学 | 23555篇 |
2023年 | 1961篇 |
2022年 | 2264篇 |
2021年 | 6379篇 |
2020年 | 3823篇 |
2019年 | 6635篇 |
2018年 | 10647篇 |
2017年 | 7265篇 |
2016年 | 7575篇 |
2015年 | 8630篇 |
2014年 | 10343篇 |
2013年 | 15535篇 |
2012年 | 25286篇 |
2011年 | 25874篇 |
2010年 | 13578篇 |
2009年 | 11162篇 |
2008年 | 22387篇 |
2007年 | 23943篇 |
2006年 | 22260篇 |
2005年 | 22145篇 |
2004年 | 20906篇 |
2003年 | 19163篇 |
2002年 | 18286篇 |
2001年 | 8040篇 |
2000年 | 7718篇 |
1999年 | 7335篇 |
1998年 | 2626篇 |
1997年 | 2178篇 |
1996年 | 1850篇 |
1995年 | 1770篇 |
1994年 | 1514篇 |
1993年 | 1435篇 |
1992年 | 4202篇 |
1991年 | 3781篇 |
1990年 | 3564篇 |
1989年 | 3281篇 |
1988年 | 3109篇 |
1987年 | 2874篇 |
1986年 | 2709篇 |
1985年 | 2540篇 |
1984年 | 2098篇 |
1983年 | 1817篇 |
1982年 | 1443篇 |
1981年 | 1204篇 |
1979年 | 1668篇 |
1978年 | 1253篇 |
1977年 | 1203篇 |
1974年 | 1336篇 |
1973年 | 1336篇 |
1972年 | 1188篇 |
1971年 | 1146篇 |
Area covered: The current review is provided to update recent developments in the clinical application of cyclin/CDK inhibitors to breast cancer with a focus on the anti-tumor immune response.
Expert opinion: The cyclin D1 gene encodes the regulatory subunit of a proline-directed serine-threonine kinase that phosphorylates several substrates. CDKs possess phosphorylation site selectivity, with the phosphate-acceptor residue preceding a proline. Several important proteins are substrates including all three retinoblastoma proteins, NRF1, GCN5, and FOXM1. Over 280 cyclin D3/CDK6 substrates have b\een identified. Given the diversity of substrates for cyclin/CDKs, and the altered thresholds for substrate phosphorylation that occurs during the cell cycle, it is exciting that small molecular inhibitors targeting cyclin D/CDK activity have encouraging results in specific tumors. 相似文献
Objectives
To determine: (i) the behaviour change techniques used by a sample of Australian physiotherapists to promote non-treatment physical activity; and (ii) whether those behaviour change techniques are different to the techniques used to encourage adherence to rehabilitation exercises.Design
Cross-sectional survey.Method
An online self-report survey was advertised to private practice and outpatient physiotherapists treating patients with musculoskeletal conditions. The use of 50 behaviour change techniques were measured using five-point Likert-type scale questions.Results
Four-hundred and eighty-six physiotherapists responded to the survey, with 216 surveys fully completed. Most respondents (85.1%) promoted non-treatment physical activity often or all of the time. Respondents frequently used 29 behaviour change techniques to promote non-treatment physical activity or encourage adherence to rehabilitation exercises. A similar number of behaviour change techniques was frequently used to encourage adherence to rehabilitation exercises (n = 28) and promote non-treatment physical activity (n = 26). Half of the behaviour change techniques included in the survey were frequently used for both promoting non-treatment physical activity and encouraging adherence to rehabilitation exercises (n = 25). Graded tasks was the most, and punishment was the least, frequently reported technique used to promote non-treatment physical activity and encourage adherence to rehabilitation exercises.Conclusions
Respondents reported using similar behaviour change techniques to promote non-treatment physical activity and encourage adherence to rehabilitation exercises. The variability in behaviour change technique use suggests the behaviour the physiotherapist is promoting influences their behaviour change technique choice. Including the frequently-used behaviour change techniques in non-treatment physical activity promotion interventions might improve their efficacy. 相似文献Areas covered: This review includes a view of the clinical classification and risk assessment in children suffering from HL. The chemotherapy more commonly employed is revisited. The use of PET/CT to evaluate the disease in order to guide therapy is analyzed. New options of chemotherapy and emerging immunotherapy are also included.
Expert opinion: In order to make the right treatment choice, a proper initial assessment of risk is mandatory. The choice of therapy in these kinds of patients must be done according to the experience of the team, and also, the cost and logistics related to the eligible scheme are very important. If possible, efforts must be made to include PET/CT in guiding therapy and avoiding overtreatment and long-term adverse effects in children. New options in immunotherapy are emerging and must be considered with caution in selected patients. 相似文献